Table 1.
Comparative studies of CSF biomarkers in autopsy/genetic-confirmed FTLD and AD cohorts.
| Study | Patients | Aβ1−42 | t-tau | p-tau181 | Diagnostic accuracy (AD vs. FTLD) |
|---|---|---|---|---|---|
| Clark et al., 2003 | (10) FTLD(74) AD*73(4) CN | AD < FTLD, CN | CN < FTLD < AD | NA | No statistical analysis of FTLD diagnostic accuracy performed |
| Grossman et al., 2005 | 73 (11) FTLD(17) AD13 CN | AD < FTLD, CN | CN, FTLD < AD | CN, FTLD < AD | t-tau |
| AUC = 0.86, sens = 74%, spec = 82.4% | |||||
| Bian et al., 2008 | (30) FTLD(19) AD13 CN | AD < FTLD, CN | CN, FTLD < AD | NA | t-tau/Aβ1−42 |
| AUC = 0.93, sens = 78.9%, spec = 96.6% | |||||
| Engelborghs et al., 2008 | (2) FTLD(73) AD*100 CN | NA | NA | NA | No statistical analysis of FTLD diagnostic accuracy performed |
| Koopman et al., 2009 | (10) FTLD(95) AD | AD < FTLD | FTLD < AD | FTLD < AD | p-tau181 |
| AUC = 0.85, sens = 91%, spec = 80% | |||||
| Tapiola et al., 2009 | (9) FTLD(83) AD | NA | NA | NA | No statistical analysis of FTLD diagnostic accuracy performed |
| Brunnstrom et al., 2010 | (12) FTLD(8) AD* | NA | NA | NA | No statistical analysis of FTLD diagnostic accuracy performed |
| Irwin et al., 2012b | (20) FTLD(41) AD* | NA | NA | NA | t-tau/Aβ1−42 |
| AUC = 0.99, sens = 90–100%, spec = 90–96% | |||||
| Toledo et al., 2012 | (71) AD(29) FTLD66 CN | AD < FTLD < CN | CN, FTLD < AD | CN, FTLD < AD | t-tau/Aβ1−42 (ELISA) |
| AUC = 0.96, sens = 90, spec = 82% | |||||
| p-tau181/Aβ1−42 (xMAP) | |||||
| AUC = 0.98, sens = 100%, spec = 88% |
Other diagnostic groups that may be present in some studies are omitted and only direct comparisons of FTLD group to AD or CN are reported. “<” or “>” denotes significant difference between groups and “,” denotes non-significant difference between groups, () denotes autopsy/genetic confirmed cohort.
CN, non-demented controls;
*
, AD group contains cases with co-morbid Lewy Body or Vascular Disease; NA, Not assessed; AUC, Area under the curve for receiver operating curve analysis; ELISA, enzyme-linked immunosorbent assay; xMAP, luminex multiplex assay.